The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients | Performance Analytics | Scinapse
Perspective
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
,,
CI 23.10
Apr 17, 2020
Published
Abstract
Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.
Research Topics
Paper Details
Title
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients